IVERIC bio, Inc.
IVERIC bio, Inc. (ISEE) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
isee · stock forecast · 24 analysts (3M) · FMP · updated Mar 26, 2024
Analyst Rating & Consensus
Based on 24 Wall Street analysts in the past 3 months
Hold
24 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$35.00
Consensus
$32.75
-18.0% upside
Low
$27.00
Median: $34.5 · Last Close: $39.95
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Consensus Target
$32.75
-18.0% upside
High Target
$35
-12.4%
Low Target
$27
-32.4%
Current Price
$39.95
as of today
Based on analyst price targets, the ISEE stock price prediction for the next 12 months ranges from $27 to $35. The consensus ISEE price forecast of $32.75 implies -18.0% upside from the current price of $39.95.
Short-Term Price Prediction
BullAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $40.55 | ↑ 1.49% |
1-day model range: $40.48–$40.61. Peak: $40.61 (+1.49%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · ISEE · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2023-05-08 | TD Cowen | Downgrade ↓ | Outperform→Perform |
| 2023-05-07 | TD Cowen | Downgrade ↓ | Outperform→Perform |
| 2023-05-04 | Baird | Downgrade ↓ | Outperform→Neutral |
| 2023-05-03 | UBS | Downgrade ↓ | Buy→Neutral |
| 2023-05-03 | Baird | Downgrade ↓ | Outperform→Neutral |
| 2023-05-02 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2023-05-02 | UBS | Downgrade ↓ | Buy→Neutral |
| 2023-05-01 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2023-05-01 | Wedbush | Downgrade ↓ | Outperform→Neutral |
| 2023-05-01 | Guggenheim | Downgrade ↓ | Buy→Neutral |
Wall Street analysts have recently issued updated ratings on IVERIC bio, Inc. (ISEE) stock. Of the recent 82 rating actions, 2 were upgrades and 26 were downgrades. 24 analysts currently cover ISEE.
Analyst Recommendation Trends
ISEE analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 6 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
—
Revenue Next Year
—
EPS This Year
—
EPS Next Year
—
EPS ForecastReported vs Estimated
Analysts forecast ISEE EPS of $— for the current fiscal year, based on estimates from 0 analysts. The ISEE revenue forecast is — for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The ISEE stock forecast is supported by two independent data sources: analyst consensus ratings from 24 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus ISEE price target is $32.75 (-18.0% upside), with an analyst consensus of Hold.
The ISEE short-term stock prediction for tomorrow is $40.55 (+1.49%).
IVERIC bio, Inc. trades on NASDAQ under the ticker ISEE. The ISEE stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 38% of covering analysts.
Frequently asked questions
ISEE forecast · 8 questionsAccording to 24 Wall Street analysts, the average 12-month ISEE price target is $32.75, with a high forecast of $35.00 and a low of $27.00. The median price target is shown in the chart above when available. This implies -18.0% potential upside from the current price of $39.95.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.